184 related articles for article (PubMed ID: 27310338)
1. Opioids in the treatment of restless legs syndrome: pharmacological and clinical aspects.
de Biase S; Merlino G; Valente M; Gigli GL
Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1035-45. PubMed ID: 27310338
[TBL] [Abstract][Full Text] [Related]
2. Prolonged release oxycodone-naloxone for treatment of severe restless legs syndrome after failure of previous treatment: a double-blind, randomised, placebo-controlled trial with an open-label extension.
Trenkwalder C; Beneš H; Grote L; García-Borreguero D; Högl B; Hopp M; Bosse B; Oksche A; Reimer K; Winkelmann J; Allen RP; Kohnen R;
Lancet Neurol; 2013 Dec; 12(12):1141-50. PubMed ID: 24140442
[TBL] [Abstract][Full Text] [Related]
3. ADMET considerations when prescribing novel therapeutics to treat restless legs syndrome.
de Biase S; Merlino G; Lorenzut S; Valente M; Gigli GL
Expert Opin Drug Metab Toxicol; 2014 Oct; 10(10):1365-80. PubMed ID: 25149093
[TBL] [Abstract][Full Text] [Related]
4. Sleep and Quality of Life Under Prolonged Release Oxycodone/Naloxone for Severe Restless Legs Syndrome: An Analysis of Secondary Efficacy Variables of a Double-Blind, Randomized, Placebo-Controlled Study with an Open-Label Extension.
Oertel WH; Hallström Y; Saletu-Zyhlarz GM; Hopp M; Bosse B; Trenkwalder C;
CNS Drugs; 2016 Aug; 30(8):749-60. PubMed ID: 27401882
[TBL] [Abstract][Full Text] [Related]
5. Oxycodone/Naloxone PR: A Review in Severe Refractory Restless Legs Syndrome.
Frampton JE
CNS Drugs; 2015 Jun; 29(6):511-8. PubMed ID: 26135898
[TBL] [Abstract][Full Text] [Related]
6. Opioids for restless legs syndrome.
de Oliveira CO; Carvalho LB; Carlos K; Conti C; de Oliveira MM; Prado LB; Prado GF
Cochrane Database Syst Rev; 2016 Jun; 2016(6):CD006941. PubMed ID: 27355187
[TBL] [Abstract][Full Text] [Related]
7. Pain, opioids, and sleep: implications for restless legs syndrome treatment.
Trenkwalder C; Zieglgänsberger W; Ahmedzai SH; Högl B
Sleep Med; 2017 Mar; 31():78-85. PubMed ID: 27964861
[TBL] [Abstract][Full Text] [Related]
8. Intractable restless legs syndrome: role of prolonged-release oxycodone-naloxone.
de Biase S; Valente M; Gigli GL
Neuropsychiatr Dis Treat; 2016; 12():417-25. PubMed ID: 26966363
[TBL] [Abstract][Full Text] [Related]
9. Investigational approaches to therapies for restless legs syndrome.
de Biase S; Merlino G; Lorenzut S; Valente M; Gigli GL
Expert Opin Investig Drugs; 2014 Jun; 23(6):847-56. PubMed ID: 24708072
[TBL] [Abstract][Full Text] [Related]
10. Targinact for restless legs syndrome.
Drug Ther Bull; 2016 Apr; 54(4):42-5. PubMed ID: 27079737
[TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy for restless legs syndrome.
Ferini-Strambi L; Marelli S
Expert Opin Pharmacother; 2014 Jun; 15(8):1127-38. PubMed ID: 24745717
[TBL] [Abstract][Full Text] [Related]
12. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications.
Hornyak M; Scholz H; Kohnen R; Bengel J; Kassubek J; Trenkwalder C
Sleep Med Rev; 2014 Apr; 18(2):153-64. PubMed ID: 23746768
[TBL] [Abstract][Full Text] [Related]
13. Non-dopaminergic vs. dopaminergic treatment options in restless legs syndrome.
Wanner V; Garcia Malo C; Romero S; Cano-Pumarega I; García-Borreguero D
Adv Pharmacol; 2019; 84():187-205. PubMed ID: 31229171
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic advances in restless legs syndrome (RLS).
Högl B; Comella C
Mov Disord; 2015 Sep; 30(11):1574-9. PubMed ID: 26371624
[TBL] [Abstract][Full Text] [Related]
15. Advancing synthetic therapies for the treatment of restless legs syndrome.
de Biase S; Pellitteri G; Gigli GL; Valente M
Expert Opin Pharmacother; 2019 Nov; 20(16):1971-1980. PubMed ID: 31424287
[No Abstract] [Full Text] [Related]
16. Restless legs syndrome-current therapies and management of augmentation.
Trenkwalder C; Winkelmann J; Inoue Y; Paulus W
Nat Rev Neurol; 2015 Aug; 11(8):434-45. PubMed ID: 26215616
[TBL] [Abstract][Full Text] [Related]
17. When restless legs syndrome turns malignant.
Schulte EC; Gross N; Slawik H; Winkelmann J
Sleep Med; 2013 Jun; 14(6):575-7. PubMed ID: 23643657
[TBL] [Abstract][Full Text] [Related]
18. ADMET considerations for restless leg syndrome drug treatments.
de Biase S; Merlino G; Lorenzut S; Valente M; Gigli GL
Expert Opin Drug Metab Toxicol; 2012 Oct; 8(10):1247-61. PubMed ID: 22808933
[TBL] [Abstract][Full Text] [Related]
19. Long-Term treatment of a patient with severe restless legs syndrome using intrathecal morphine.
Hornyak M; Kaube H
Neurology; 2012 Dec; 79(24):2361-2. PubMed ID: 23197746
[TBL] [Abstract][Full Text] [Related]
20. Where dopamine meets opioids: a meta-analysis of the placebo effect in restless legs syndrome treatment studies.
Fulda S; Wetter TC
Brain; 2008 Apr; 131(Pt 4):902-17. PubMed ID: 17932100
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
